Merck & Co. Inc.
(NYSE:MRK) stock edged higher Thursday after the drugmaker reported third-quarter results that topped Wall Street revenue expectations and upbeat financial guidance. 08.
313 billion, reflecting increased contributions from new products as well as strength in Oncology and Animal Health. 6 billion in global sales, up 6% year over year, driven by usage in tumors predominantly affecting women, including those with certain cervical and breast cancers, as well as increased use of Keytruda plus Padcev in urothelial cancer.
Merck also saw continued uptake in earlier-stage head and neck cancer. Keytruda Qlex (more convenient under-the-skin injection) sales reached $830 million.
S. customer purchases last year created a headwind to growth for Keytruda, but this was largely offset by an increase in channel inventory, which is expected to unwind in the fourth quarter.
S. reflecting favorable public-sector purchasing patterns (CDC purchase) and higher net pricing.
676 billion, driven by growth across its Livestock and Companion Animal portfolios. Winrevair, Merck’s pulmonary arterial hypertension treatment, posted sales of $694 million, up 93% from a year earlier.
S. 65.
12 per share related to the global license agreement with SciBrunch. 052 billion.
Merck expects modest top-line growth in 2027. 05 at the time of publication on Thursday, according to Benzinga Pro data.
